{"id":309550,"date":"2026-02-23T20:38:25","date_gmt":"2026-02-23T15:38:25","guid":{"rendered":"https:\/\/www.botslash.com\/market-ur\/technology-sector-sees-slowdown-in-m-gilead-acquires-arcus-en\/"},"modified":"2026-02-23T20:38:25","modified_gmt":"2026-02-23T15:38:25","slug":"technology-sector-sees-slowdown-in-m-gilead-acquires-arcus-en","status":"publish","type":"post","link":"https:\/\/www.botslash.com\/en\/market\/technology-sector-sees-slowdown-in-m-gilead-acquires-arcus-en\/","title":{"rendered":"Technology Sector Sees Slowdown in M&amp;A; Gilead Acquires Arcus"},"content":{"rendered":"<p>Mergers and acquisitions (M&amp;A) activity in the technology sector has significantly slowed down as companies reassess their investment and growth strategies amid changing market conditions. In a notable development within the biotechnology field, Gilead Sciences has entered into an agreement to acquire Arcus Therapeutics, aiming to strengthen its product portfolio and expand its presence in biotechnology. Meanwhile, global pharmaceutical company Merck has announced plans to spin off its pharmaceutical division, a strategic move intended to improve operational efficiency and focus on core business areas. These decisions reflect ongoing transformations in healthcare and technology sectors, where companies are restructuring their business models to adapt to evolving market demands. The decline in M&amp;A activity is linked to global economic uncertainties and a cautious investment climate. Gilead\u2019s acquisition of Arcus symbolizes its growth strategy in biotechnology, while Merck\u2019s separation of its pharma division represents a significant step toward enhancing operational effectiveness. These changes are expected to impact the market positions of these companies and may lead to broader shifts in the industry\u2019s overall structure.<\/p>\n<p><strong>Source:<\/strong> <a href=\"https:\/\/www.binance.com\/en\/square\/post\/294788732666849?utm_source=BinanceNewsRSS\" target=\"_blank\" rel=\"nofollow noopener\">binance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mergers and acquisitions (M&amp;A) activity in the technology sector has significantly slowed down as companies reassess their investment and growth strategies amid changing market conditions. In a notable development within the biotechnology field, Gilead Sciences has entered into an agreement to acquire Arcus Therapeutics, aiming to strengthen its product portfolio and expand its presence in biotechnology. Meanwhile, global pharmaceutical company Merck has announced plans to spin off its pharmaceutical division, a strategic move intended to improve operational efficiency and focus on core business areas. These decisions reflect ongoing transformations in healthcare and technology sectors, where companies are restructuring their business models to adapt to evolving market demands. The decline in M&amp;A activity is linked to global economic uncertainties and a cautious investment climate. Gilead\u2019s acquisition of Arcus symbolizes its growth strategy in biotechnology, while Merck\u2019s separation of its pharma division represents a significant step toward enhancing operational effectiveness. These changes are expected to impact the market positions of these companies and may lead to broader shifts in the industry\u2019s overall structure. Source: binance<\/p>\n","protected":false},"author":0,"featured_media":221670,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[134],"tags":[],"class_list":["post-309550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-ur"],"_links":{"self":[{"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/posts\/309550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/comments?post=309550"}],"version-history":[{"count":0,"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/posts\/309550\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/media\/221670"}],"wp:attachment":[{"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/media?parent=309550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/categories?post=309550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.botslash.com\/en\/wp-json\/wp\/v2\/tags?post=309550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}